Concept
Critical Illness
4 studiesEvidence last moved Sep 20, 2026
Critical illness is the state in which organ function fails fast enough to threaten life. The research problem running through these studies is that the syndromes used to organise it — sepsis, acute kidney injury, a transmission cluster — are administrative categories containing biologically different patients.
Intensive care trials enrol by syndrome, and syndrome-level enrolment is the standing explanation for why so many of them are null. Each study here identifies a subgroup or a consequence the syndrome label does not capture.
Studies
4
Findings
4
4 supporting · 0 challenging · 0 qualifying citations
Open tensions
1
Latest change
Concept page published
Critical Illness
Currently
What we know
- A cheap, widely available test identifies the subgroup, which is what makes it actionable.
- The two-year cognitive gap is larger in relative terms than the one-week gap.
- A mean reproduction number would describe none of these events.
- The composition difference is the durable finding; the specific gene list is not.
Largest unresolved question
These studies subdivide critical illness with very different evidentiary weight. Macrophage activation-like syndrome is defined by a specific threshold and validated in a second cohort, while the sepsis transcriptomic clusters rest on ten arrays with algorithms the authors acknowledge overfit small public datasets.
Common misconceptions
Identifying a high-mortality subgroup means treating it differently will help.
Macrophage activation-like syndrome is an observational classification: high ferritin identifies patients who die more often. Nothing in the study shows that targeted treatment changes that, and the classification itself modified the HScore by omitting bone-marrow haemophagocytosis.
Surviving acute kidney injury means the episode is over.
Cognitive impairment was still more than three times more common at two years (13.0% against 3.4%, aOR 3.03), with chronic kidney disease and post-discharge mortality also elevated. Whether the injury itself or overall illness severity drives this is not resolved.
Related
Claim ledger
What the evidence shows
Drawn from 4 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.
A cheap, widely available test identifies the subgroup, which is what makes it actionable.
A small, identifiable subgroup of sepsis carries very high mortality. Macrophage activation-like syndrome occurred in 3.7% and 4.3% of two cohorts, with ferritin above 4420 ng/ml over 97% specific for it and associated with 28-day mortality around 66% (OR 4.07).
The two-year cognitive gap is larger in relative terms than the one-week gap.
The consequences of critical illness extend years past discharge. Among patients with acute kidney injury, in-hospital death was 11.9% against 4.2%, cognitive impairment was 37.3% against 13.5% at one week (aOR 2.31) and 13.0% against 3.4% at two years (aOR 3.03), with chronic kidney disease at one year 7.6% against 2.8%.
A mean reproduction number would describe none of these events.
Transmission in healthcare settings is driven by rare individuals rather than by an average rate. Healthcare-linked MERS ranged from 43.5% to 100% of cases by outbreak, with Korea's index patient infecting 30 others and two second-generation patients infecting 80 and 23.
The composition difference is the durable finding; the specific gene list is not.
Immune cell composition differs in sepsis, but small-sample transcriptomics identifies hub genes unreliably. Single-cell and microarray analysis found six t-SNE clusters and seven hub genes (CD28, CD3D, CD2, CD4, IL7R, LCK, CD3E), six of them reduced in sepsis — from ten sepsis arrays, where hub-gene algorithms overfit.
Debates
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.
These studies subdivide critical illness with very different evidentiary weight. Macrophage activation-like syndrome is defined by a specific threshold and validated in a second cohort, while the sepsis transcriptomic clusters rest on ten arrays with algorithms the authors acknowledge overfit small public datasets.
These studies subdivide critical illness with very different evidentiary weight. Macrophage activation-like syndrome is defined by a specific threshold and validated in a second cohort, while the sepsis transcriptomic clusters rest on ten arrays with algorithms the authors acknowledge overfit small public datasets.
Study Role Design N Population Outcome Can ferritin flag deadly macrophage-like sepsis? Supports CohortProspective Greek sepsis cohorts (test n=3417, validation n=1704) plus a Swedish ferritin-validation cohort (n=109) classifying macrophage activation-like syndrome (MALS) N=5121 · 3417 test + 1704 validation patients with infection and SIRS; ferritin repeated on day 3 in 747; Swedish cohort n=109 Adults with infection plus SIRS enrolled by the Hellenic Sepsis Study Group (plus an independent Swedish sepsis cohort) MALS frequency, 10-day mortality, and ferritin as a diagnostic/prognostic biomarker Which immune genes drop in sepsis single-cell maps? Supports Computational / modellingGEO GSE28750 bulk microarray (10 sepsis vs 20 controls) plus single-cell clustering, hub-gene network algorithms, and follow-up animal immunoassays N=30 · GSE28750: 10 sepsis and 20 normal samples; 61 DEGs; 7 hub genes; plus in vivo animal validation assays Public human GEO sepsis vs control transcriptomes (GSE28750) with single-cell maps and animal immune-factor assays Differentially expressed and hub immune genes (CD28, CD3D, CD2, CD4, IL7R, LCK, CD3E) and immune-cell cluster shifts in sepsis
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Timeline
How understanding moved
Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.
2026
Concept page published
Critical Illness
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Rewordings are not listed.
- Concept page published
Papers
4 studies in this library bear on Critical Illness, ordered by citations.
- Are hospital MERS outbreaks just like SARS?
Comparing hospital clusters, MERS and SARS both ignite via early super-spreaders then drop below R=1 within 3–5 generations; a >100-case outbreak is about twice as likely for SARS (2% vs 1%), while MERS transmission is more heterogeneous.
- Can ferritin flag deadly macrophage-like sepsis?
In 5,121 Greek patients with infection and SIRS, macrophage activation-like syndrome (MALS) occurred in ~4% and independently predicted 10-day death; ferritin above 4420 ng/ml marked ~66% 28-day mortality.
- Does malaria-related kidney injury leave lasting brain and kidney harm?
In 479 Ugandan children with severe malaria, KDIGO AKI (35%) tracked higher death (aHR 2.30), more cognitive impairment at 2 years (aOR 3.03), and more CKD (7.6% vs 2.8%).
- Which immune genes drop in sepsis single-cell maps?
In GSE28750 (10 sepsis vs 20 controls), 61 DEGs and single-cell t-SNE (T/NK/monocyte/megakaryocyte/DC/B cells) pointed to seven T-cell hub genes; six of them were lower in sepsis, with animal assays as follow-up.
Compare studies
Select 2–10 studies. Design and N are labels, not a ranking.
Nothing selected yet.
Questions
What is still open
These studies subdivide critical illness with very different evidentiary weight. Macrophage activation-like syndrome is defined by a specific threshold and validated in a second cohort, while the sepsis transcriptomic clusters rest on ten arrays with algorithms the authors acknowledge overfit small public datasets.
Ask PaperFren about Critical Illness
Study this conceptflashcards and short-answer questions
Why does enrolling trials by syndrome plausibly explain null results in critical care?
Because a syndrome label can contain biologically distinct groups whose responses cancel. Macrophage activation-like syndrome is under 5% of sepsis admissions but carries roughly 66% 28-day mortality and a specific immunological profile. A trial of an immunomodulator enrolling all sepsis would dilute any effect in that subgroup across the 95% who do not have it.
What does a superspreading pattern change about infection control evidence?
It makes averages misleading and individual events decisive. Korea's index patient infected 30 others and two second-generation patients infected 80 and 23, while healthcare-linked proportions ranged from 43.5% to 100% across outbreaks. With few fully resolved transmission trees and reporting biased toward large clusters, the reproduction number and dispersion are imprecise, and simulations cannot identify which control measure would have stopped a particular event.
How much weight should a seven-gene hub list from ten arrays carry?
Very little as a gene list, more as a composition finding. The authors state that hub-gene algorithms overfit small public datasets and that ten sepsis arrays cannot define treatment targets. The robust observation is that immune cell composition differs from controls; the specific identities of CD28, CD3D and the rest would likely change with a different sample or algorithm.